title: Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy.
abstract: The renoprotective effect of losartan and quinaprilat was tested in two different animal models of renal failure [female Wistar rats, single administration of 0.5 mg uranyl nitrate (UN)/100 g body wt. or 5/6 nephrectomy (5/6NX)]. Losartan (1 mg/100 g body weight [wt.]) and quinaprilat (1 mg/100 g body wt.) were administered intraperitoneally, once daily, starting 10 days after UN and one week after 5/6NX till the end of 10 weeks experimental period. Parameters characterizing the therapeutic effect were blood pressure, urinary protein excretion 4 and 10 weeks after the injury, and p-aminohippurate accumulation in renal cortical slices in vitro, hydroxy-proline concentration in renal tissue and morphology at the end of the experiment. Summarizing our results we state: (1) the angiotensin 1 receptor blocker losartan is more effective in UN-treated than in 5/6 NX rats, and (2) the angiotensin converting enzyme inhibitor quinaprilat is more effective than losartan because of the amelioration of blood pressure and OH-proline concentration in renal tissue of UN-treated rats.
authors.affiliation: Institute of Pharmacology and Toxicology, Friedrich Schiller University Jena, Germany. dorothea.appenroth@mti.uni-jena.de
authors.forename: Dorothea
authors.initials: D
authors.lastname: Appenroth
authors.forename: Ralf
authors.initials: R
authors.lastname: Beutinger
authors.forename: Amelie
authors.initials: A
authors.lastname: Lupp
authors.forename: Christian
authors.initials: C
authors.lastname: Fleck
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D006909:Hydroxyproline / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D019808:Losartan / Q000008:administration & dosage / Q000627:therapeutic use*; D009392:Nephrectomy; D011507:Proteinuria / Q000188:drug therapy; D051381:Rats; D017208:Rats, Wistar; D044005:Tetrahydroisoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D014502:Uranyl Nitrate / Q000633:toxicity; D010130:p-Aminohippuric Acid / Q000378:metabolism
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D044005:Tetrahydroisoquinolines; D014502:Uranyl Nitrate; C054501:quinaprilat; D019808:Losartan; D006909:Hydroxyproline; D010130:p-Aminohippuric Acid